Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Radiosurgery Branches Out

Executive Summary

The convergence of advancing technology and the push for more effective, noninvasive cancer treatments is helping to build the perfect storm of innovation for the field of stereotactic radiosurgery. SRS allows high doses of precisely focused ablative energy to be delivered to targeted tissues with a minimum of damage to surrounding areas. It has been used for years to treat tumors in the head and neck, where patient movement can be effectively restrained with frames to protect healthy tissue. However, technological advances are now making the procedure more viable for tumors in other parts of the body, and that opens the door to treating cancers in the lung, prostate, breast, and beyond.
Advertisement

Related Content

Market & Industry Briefs
Market & Industry Briefs
Imaging Market Could See Brighter Days Ahead
Advancing Ablative Tumor Therapies Into Primary Treatments

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT035407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel